Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases

E. Miserocchi, I. Pontikaki, G. Modorati, M. Gattinara, P. L. Meroni, V. Gerloni

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Rituximab is a monoclonal antibody directed against the CD20 antigen expressed on B cells and widely used in the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis. There is a growing amount of literature which suggests that rituximab may be useful for inflammatory ocular diseases and intraocular lymphoma. Few cases have been reported on treatment of refractory scleritis, peripherative ulcerative keratitis, uveitis and ocular surface inflammatory disorders. Rituximab may be effective in the treatment of ocular inflammatory diseases in particular the most aggressive, recalcitrant and sight-threatening forms of inflammation such as uveitis associated to juvenile idiopathic arthritis. We review the literature covering the use of Rituximab in these conditions and report our results on the efficacy of Rituximab in the treatment of 8 children with very severe and long-standing uveitis who failed to respond to one or more TNF blockers. Our patients showed improvement in activity of uveitis, reduction of concomitant corticosteroids and immunosuppressants after a mean follow-up time of 14.87. months on rituximab. No serious adverse events were encountered in our treated patients. Although further studies are needed for assessing the efficacy of rituximab and the exact dosing regimen, rituximab may be considered as a treatment alternative in patients with the most aggressive forms of inflammatory ocular diseases who fail to respond to conventional and anti-TNF immunosuppressive agents.

Original languageEnglish
Pages (from-to)35-39
Number of pages5
JournalAutoimmunity Reviews
Volume11
Issue number1
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Eye Diseases
Monoclonal Antibodies
Uveitis
Therapeutics
Immunosuppressive Agents
Intraocular Lymphoma
CD20 Antigens
Scleritis
Corneal Ulcer
Juvenile Arthritis
Rituximab
Non-Hodgkin's Lymphoma
Rheumatoid Arthritis
Adrenal Cortex Hormones
B-Lymphocytes
Inflammation

Keywords

  • Juvenile idiopathic arthritis
  • Ocular inflammatory diseases
  • Rituximab

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. / Miserocchi, E.; Pontikaki, I.; Modorati, G.; Gattinara, M.; Meroni, P. L.; Gerloni, V.

In: Autoimmunity Reviews, Vol. 11, No. 1, 11.2011, p. 35-39.

Research output: Contribution to journalArticle

Miserocchi, E. ; Pontikaki, I. ; Modorati, G. ; Gattinara, M. ; Meroni, P. L. ; Gerloni, V. / Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. In: Autoimmunity Reviews. 2011 ; Vol. 11, No. 1. pp. 35-39.
@article{24da46263cc04016a86a135ca26efc3e,
title = "Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases",
abstract = "Rituximab is a monoclonal antibody directed against the CD20 antigen expressed on B cells and widely used in the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis. There is a growing amount of literature which suggests that rituximab may be useful for inflammatory ocular diseases and intraocular lymphoma. Few cases have been reported on treatment of refractory scleritis, peripherative ulcerative keratitis, uveitis and ocular surface inflammatory disorders. Rituximab may be effective in the treatment of ocular inflammatory diseases in particular the most aggressive, recalcitrant and sight-threatening forms of inflammation such as uveitis associated to juvenile idiopathic arthritis. We review the literature covering the use of Rituximab in these conditions and report our results on the efficacy of Rituximab in the treatment of 8 children with very severe and long-standing uveitis who failed to respond to one or more TNF blockers. Our patients showed improvement in activity of uveitis, reduction of concomitant corticosteroids and immunosuppressants after a mean follow-up time of 14.87. months on rituximab. No serious adverse events were encountered in our treated patients. Although further studies are needed for assessing the efficacy of rituximab and the exact dosing regimen, rituximab may be considered as a treatment alternative in patients with the most aggressive forms of inflammatory ocular diseases who fail to respond to conventional and anti-TNF immunosuppressive agents.",
keywords = "Juvenile idiopathic arthritis, Ocular inflammatory diseases, Rituximab",
author = "E. Miserocchi and I. Pontikaki and G. Modorati and M. Gattinara and Meroni, {P. L.} and V. Gerloni",
year = "2011",
month = "11",
doi = "10.1016/j.autrev.2011.07.001",
language = "English",
volume = "11",
pages = "35--39",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases

AU - Miserocchi, E.

AU - Pontikaki, I.

AU - Modorati, G.

AU - Gattinara, M.

AU - Meroni, P. L.

AU - Gerloni, V.

PY - 2011/11

Y1 - 2011/11

N2 - Rituximab is a monoclonal antibody directed against the CD20 antigen expressed on B cells and widely used in the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis. There is a growing amount of literature which suggests that rituximab may be useful for inflammatory ocular diseases and intraocular lymphoma. Few cases have been reported on treatment of refractory scleritis, peripherative ulcerative keratitis, uveitis and ocular surface inflammatory disorders. Rituximab may be effective in the treatment of ocular inflammatory diseases in particular the most aggressive, recalcitrant and sight-threatening forms of inflammation such as uveitis associated to juvenile idiopathic arthritis. We review the literature covering the use of Rituximab in these conditions and report our results on the efficacy of Rituximab in the treatment of 8 children with very severe and long-standing uveitis who failed to respond to one or more TNF blockers. Our patients showed improvement in activity of uveitis, reduction of concomitant corticosteroids and immunosuppressants after a mean follow-up time of 14.87. months on rituximab. No serious adverse events were encountered in our treated patients. Although further studies are needed for assessing the efficacy of rituximab and the exact dosing regimen, rituximab may be considered as a treatment alternative in patients with the most aggressive forms of inflammatory ocular diseases who fail to respond to conventional and anti-TNF immunosuppressive agents.

AB - Rituximab is a monoclonal antibody directed against the CD20 antigen expressed on B cells and widely used in the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis. There is a growing amount of literature which suggests that rituximab may be useful for inflammatory ocular diseases and intraocular lymphoma. Few cases have been reported on treatment of refractory scleritis, peripherative ulcerative keratitis, uveitis and ocular surface inflammatory disorders. Rituximab may be effective in the treatment of ocular inflammatory diseases in particular the most aggressive, recalcitrant and sight-threatening forms of inflammation such as uveitis associated to juvenile idiopathic arthritis. We review the literature covering the use of Rituximab in these conditions and report our results on the efficacy of Rituximab in the treatment of 8 children with very severe and long-standing uveitis who failed to respond to one or more TNF blockers. Our patients showed improvement in activity of uveitis, reduction of concomitant corticosteroids and immunosuppressants after a mean follow-up time of 14.87. months on rituximab. No serious adverse events were encountered in our treated patients. Although further studies are needed for assessing the efficacy of rituximab and the exact dosing regimen, rituximab may be considered as a treatment alternative in patients with the most aggressive forms of inflammatory ocular diseases who fail to respond to conventional and anti-TNF immunosuppressive agents.

KW - Juvenile idiopathic arthritis

KW - Ocular inflammatory diseases

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=80855138673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80855138673&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2011.07.001

DO - 10.1016/j.autrev.2011.07.001

M3 - Article

C2 - 21763790

AN - SCOPUS:80855138673

VL - 11

SP - 35

EP - 39

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 1

ER -